Publication Repository

The STAMPEDE trial has had a number of its results thus far published. Please find below a list of each of these publications and a video explaining the ways in which we disseminate results.

• 2023 ​Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol The Lancet
• 2022 Accumulation of copy number alterations and clinical progression across advanced prostate cancer Genome Medicine
• 2022 Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial PLOS Medicine
• 2022 Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial JNCI
• 2022 Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data PLOS ONE
• 2022 Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial IJC
• 2021 Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer A Secondary Analysis of a Randomized Clinical Trial JAMA Oncology 
• 2021 Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
• 2021 Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial Journal of clinical oncology
• 2020 The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison European Urology Oncology
• 2020 Adding new experimental arms to randomised clinical trials: Impact on error rates Clinical Trials 
• 2020 Genomic profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial Journal of Clinical Oncology
• 2019 Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer European Urology
• 2019 Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial Annals of Oncology
• 2019 This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols Trials
• 2019 Mind the gap? The platform trial as a working environment Trials
• 2019 Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons Trials
• 2018 - What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Annals of Oncology
• 2018 Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial The Lancet
• 2018 Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness European Urology Oncology 
• 2018 Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol Annals of Oncology
• 2018 Transdermal Oestradiol as a method of androgen suppression for Prostate cancer within the STAMPEDE trial platform British Journal of Urology International
• 2017 Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols Clinical Trials
• 2017 Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy New England Journal of Medicine
• 2017 Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multiustage, Platform, Randomized Controlled Trial Journal of Clinical Oncology
• 2016 Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform European Urology
• 2016 Failure-free survival and radiotherapy in patients with newly-diagnosed non-metastatic prostate cancer: Data from patients in the Control Arm of the STAMPEDE trial (Open Access publication) JAMA Oncology
• 2015 Survival with Newly Diagnosed Metastatic Prostate Cancer in the ‘‘Docetaxel Era’’: Data from 917 Patients in the Control Arm of the STAMPEDE Trial European Urology
• 2015 Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial The Lancet
• 2015 Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data The Lancet Oncology
• 2014 Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial European Urology
• 2013 Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial British Journal of Urology International 
• 2013 Prostate Radiotherapy for Men with Metastatic Disease: A New Comparison in the STAMPEDE Trial Clinical Oncology
• 2012 Flexible trial design in practice-stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial Trials
• 2012 Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial The Lancet Oncology
• 2009 Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial Trials
• 2008 Speeding up the evaluation of new agents in cancer Journal of the National Cancer Institute

Researchers have a responsibility to publicise the results of their trial. This is usually done at conferences and in medical journals, and sometimes in the press. This video explores how the results of our trials are communicated to different groups.